img

Global Anti-Tuberculosis Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-Tuberculosis Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Tuberculosis is a chronic wasting infectious disease caused by Mycobacterium tuberculosis. The drugs used to treat this disease are anti-tuberculosis drugs.
The global Anti-Tuberculosis Drug market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Anti-Tuberculosis Drug is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Anti-Tuberculosis Drug is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Anti-Tuberculosis Drug is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Anti-Tuberculosis Drug include Lupin, Otsuka, Sanofi, Prizer, Abbott and NOVARTIS, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Anti-Tuberculosis Drug, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Anti-Tuberculosis Drug by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Anti-Tuberculosis Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Anti-Tuberculosis Drug market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Lupin
Otsuka
Sanofi
Prizer
Abbott
NOVARTIS
By Type
First-Line Anti-Tuberculosis Drugs
Second-Line Anti-Tuberculosis Drugs
By Application
Hospital
Clinic
Others
Sales by Region
North America
United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Anti-Tuberculosis Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Anti-Tuberculosis Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Tuberculosis Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Anti-Tuberculosis Drug Definition
1.2 Market by Type
1.2.1 Global Anti-Tuberculosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 First-Line Anti-Tuberculosis Drugs
1.2.3 Second-Line Anti-Tuberculosis Drugs
1.3 Market Segment by Application
1.3.1 Global Anti-Tuberculosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Anti-Tuberculosis Drug Sales
2.1 Global Anti-Tuberculosis Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Anti-Tuberculosis Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Anti-Tuberculosis Drug Revenue by Region
2.3.1 Global Anti-Tuberculosis Drug Revenue by Region (2018-2024)
2.3.2 Global Anti-Tuberculosis Drug Revenue by Region (2024-2034)
2.4 Global Anti-Tuberculosis Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Anti-Tuberculosis Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Anti-Tuberculosis Drug Sales Quantity by Region
2.6.1 Global Anti-Tuberculosis Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Anti-Tuberculosis Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Anti-Tuberculosis Drug Sales Quantity by Manufacturers
3.1.1 Global Anti-Tuberculosis Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Anti-Tuberculosis Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Anti-Tuberculosis Drug Sales in 2022
3.2 Global Anti-Tuberculosis Drug Revenue by Manufacturers
3.2.1 Global Anti-Tuberculosis Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Anti-Tuberculosis Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Anti-Tuberculosis Drug Revenue in 2022
3.3 Global Anti-Tuberculosis Drug Sales Price by Manufacturers
3.4 Global Key Players of Anti-Tuberculosis Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-Tuberculosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-Tuberculosis Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-Tuberculosis Drug, Product Offered and Application
3.8 Global Key Manufacturers of Anti-Tuberculosis Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Anti-Tuberculosis Drug Sales Quantity by Type
4.1.1 Global Anti-Tuberculosis Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Anti-Tuberculosis Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Anti-Tuberculosis Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Anti-Tuberculosis Drug Revenue by Type
4.2.1 Global Anti-Tuberculosis Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Anti-Tuberculosis Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Anti-Tuberculosis Drug Revenue Market Share by Type (2018-2034)
4.3 Global Anti-Tuberculosis Drug Price by Type
4.3.1 Global Anti-Tuberculosis Drug Price by Type (2018-2024)
4.3.2 Global Anti-Tuberculosis Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Anti-Tuberculosis Drug Sales Quantity by Application
5.1.1 Global Anti-Tuberculosis Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Anti-Tuberculosis Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Anti-Tuberculosis Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Anti-Tuberculosis Drug Revenue by Application
5.2.1 Global Anti-Tuberculosis Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Anti-Tuberculosis Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Anti-Tuberculosis Drug Revenue Market Share by Application (2018-2034)
5.3 Global Anti-Tuberculosis Drug Price by Application
5.3.1 Global Anti-Tuberculosis Drug Price by Application (2018-2024)
5.3.2 Global Anti-Tuberculosis Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Anti-Tuberculosis Drug Sales by Company
6.1.1 North America Anti-Tuberculosis Drug Revenue by Company (2018-2024)
6.1.2 North America Anti-Tuberculosis Drug Sales Quantity by Company (2018-2024)
6.2 North America Anti-Tuberculosis Drug Market Size by Type
6.2.1 North America Anti-Tuberculosis Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Anti-Tuberculosis Drug Revenue by Type (2018-2034)
6.3 North America Anti-Tuberculosis Drug Market Size by Application
6.3.1 North America Anti-Tuberculosis Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Anti-Tuberculosis Drug Revenue by Application (2018-2034)
6.4 North America Anti-Tuberculosis Drug Market Size by Country
6.4.1 North America Anti-Tuberculosis Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Anti-Tuberculosis Drug Revenue by Country (2018-2034)
6.4.3 North America Anti-Tuberculosis Drug Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Anti-Tuberculosis Drug Sales by Company
7.1.1 Europe Anti-Tuberculosis Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Anti-Tuberculosis Drug Revenue by Company (2018-2024)
7.2 Europe Anti-Tuberculosis Drug Market Size by Type
7.2.1 Europe Anti-Tuberculosis Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Anti-Tuberculosis Drug Revenue by Type (2018-2034)
7.3 Europe Anti-Tuberculosis Drug Market Size by Application
7.3.1 Europe Anti-Tuberculosis Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Anti-Tuberculosis Drug Revenue by Application (2018-2034)
7.4 Europe Anti-Tuberculosis Drug Market Size by Country
7.4.1 Europe Anti-Tuberculosis Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Anti-Tuberculosis Drug Revenue by Country (2018-2034)
7.4.3 Europe Anti-Tuberculosis Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Anti-Tuberculosis Drug Sales by Company
8.1.1 China Anti-Tuberculosis Drug Sales Quantity by Company (2018-2024)
8.1.2 China Anti-Tuberculosis Drug Revenue by Company (2018-2024)
8.2 China Anti-Tuberculosis Drug Market Size by Type
8.2.1 China Anti-Tuberculosis Drug Sales Quantity by Type (2018-2034)
8.2.2 China Anti-Tuberculosis Drug Revenue by Type (2018-2034)
8.3 China Anti-Tuberculosis Drug Market Size by Application
8.3.1 China Anti-Tuberculosis Drug Sales Quantity by Application (2018-2034)
8.3.2 China Anti-Tuberculosis Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Anti-Tuberculosis Drug Sales by Company
9.1.1 APAC Anti-Tuberculosis Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Anti-Tuberculosis Drug Revenue by Company (2018-2024)
9.2 APAC Anti-Tuberculosis Drug Market Size by Type
9.2.1 APAC Anti-Tuberculosis Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Anti-Tuberculosis Drug Revenue by Type (2018-2034)
9.3 APAC Anti-Tuberculosis Drug Market Size by Application
9.3.1 APAC Anti-Tuberculosis Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Anti-Tuberculosis Drug Revenue by Application (2018-2034)
9.4 APAC Anti-Tuberculosis Drug Market Size by Region
9.4.1 APAC Anti-Tuberculosis Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Anti-Tuberculosis Drug Revenue by Region (2018-2034)
9.4.3 APAC Anti-Tuberculosis Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Anti-Tuberculosis Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Anti-Tuberculosis Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Anti-Tuberculosis Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Lupin
11.1.1 Lupin Company Information
11.1.2 Lupin Overview
11.1.3 Lupin Anti-Tuberculosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Lupin Anti-Tuberculosis Drug Products and Services
11.1.5 Lupin Anti-Tuberculosis Drug SWOT Analysis
11.1.6 Lupin Recent Developments
11.2 Otsuka
11.2.1 Otsuka Company Information
11.2.2 Otsuka Overview
11.2.3 Otsuka Anti-Tuberculosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Otsuka Anti-Tuberculosis Drug Products and Services
11.2.5 Otsuka Anti-Tuberculosis Drug SWOT Analysis
11.2.6 Otsuka Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Anti-Tuberculosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Sanofi Anti-Tuberculosis Drug Products and Services
11.3.5 Sanofi Anti-Tuberculosis Drug SWOT Analysis
11.3.6 Sanofi Recent Developments
11.4 Prizer
11.4.1 Prizer Company Information
11.4.2 Prizer Overview
11.4.3 Prizer Anti-Tuberculosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Prizer Anti-Tuberculosis Drug Products and Services
11.4.5 Prizer Anti-Tuberculosis Drug SWOT Analysis
11.4.6 Prizer Recent Developments
11.5 Abbott
11.5.1 Abbott Company Information
11.5.2 Abbott Overview
11.5.3 Abbott Anti-Tuberculosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Abbott Anti-Tuberculosis Drug Products and Services
11.5.5 Abbott Anti-Tuberculosis Drug SWOT Analysis
11.5.6 Abbott Recent Developments
11.6 NOVARTIS
11.6.1 NOVARTIS Company Information
11.6.2 NOVARTIS Overview
11.6.3 NOVARTIS Anti-Tuberculosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 NOVARTIS Anti-Tuberculosis Drug Products and Services
11.6.5 NOVARTIS Anti-Tuberculosis Drug SWOT Analysis
11.6.6 NOVARTIS Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Anti-Tuberculosis Drug Value Chain Analysis
12.2 Anti-Tuberculosis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-Tuberculosis Drug Production Mode & Process
12.4 Anti-Tuberculosis Drug Sales and Marketing
12.4.1 Anti-Tuberculosis Drug Sales Channels
12.4.2 Anti-Tuberculosis Drug Distributors
12.5 Anti-Tuberculosis Drug Customers
13 Market Dynamics
13.1 Anti-Tuberculosis Drug Industry Trends
13.2 Anti-Tuberculosis Drug Market Drivers
13.3 Anti-Tuberculosis Drug Market Challenges
13.4 Anti-Tuberculosis Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-Tuberculosis Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of First-Line Anti-Tuberculosis Drugs
Table 3. Major Manufacturers of Second-Line Anti-Tuberculosis Drugs
Table 4. Global Anti-Tuberculosis Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Anti-Tuberculosis Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Anti-Tuberculosis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Anti-Tuberculosis Drug Revenue Market Share by Region (2018-2024)
Table 8. Global Anti-Tuberculosis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Anti-Tuberculosis Drug Revenue Market Share by Region (2024-2034)
Table 10. Global Anti-Tuberculosis Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Anti-Tuberculosis Drug Sales by Region (2018-2024) & (K Units)
Table 12. Global Anti-Tuberculosis Drug Sales Market Share by Region (2018-2024)
Table 13. Global Anti-Tuberculosis Drug Sales by Region (2024-2034) & (K Units)
Table 14. Global Anti-Tuberculosis Drug Sales Market Share by Region (2024-2034)
Table 15. Global Anti-Tuberculosis Drug Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Anti-Tuberculosis Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Anti-Tuberculosis Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Anti-Tuberculosis Drug Revenue Share by Manufacturers (2018-2024)
Table 19. Global Anti-Tuberculosis Drug Price by Manufacturers 2018-2024 (US$/Unit)
Table 20. Global Key Players of Anti-Tuberculosis Drug, Industry Ranking, 2021 VS 2022
Table 21. Global Anti-Tuberculosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Anti-Tuberculosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Tuberculosis Drug as of 2022)
Table 23. Global Key Manufacturers of Anti-Tuberculosis Drug, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Anti-Tuberculosis Drug, Product Offered and Application
Table 25. Global Key Manufacturers of Anti-Tuberculosis Drug, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Anti-Tuberculosis Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Anti-Tuberculosis Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Anti-Tuberculosis Drug Sales Quantity Share by Type (2018-2024)
Table 30. Global Anti-Tuberculosis Drug Sales Quantity Share by Type (2024-2034)
Table 31. Global Anti-Tuberculosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Anti-Tuberculosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Anti-Tuberculosis Drug Revenue Share by Type (2018-2024)
Table 34. Global Anti-Tuberculosis Drug Revenue Share by Type (2024-2034)
Table 35. Anti-Tuberculosis Drug Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Anti-Tuberculosis Drug Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Anti-Tuberculosis Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Anti-Tuberculosis Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Anti-Tuberculosis Drug Sales Quantity Share by Application (2018-2024)
Table 40. Global Anti-Tuberculosis Drug Sales Quantity Share by Application (2024-2034)
Table 41. Global Anti-Tuberculosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Anti-Tuberculosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Anti-Tuberculosis Drug Revenue Share by Application (2018-2024)
Table 44. Global Anti-Tuberculosis Drug Revenue Share by Application (2024-2034)
Table 45. Anti-Tuberculosis Drug Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Anti-Tuberculosis Drug Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. North America Anti-Tuberculosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Anti-Tuberculosis Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Anti-Tuberculosis Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Anti-Tuberculosis Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Anti-Tuberculosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Anti-Tuberculosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Anti-Tuberculosis Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Anti-Tuberculosis Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Anti-Tuberculosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Anti-Tuberculosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Anti-Tuberculosis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Anti-Tuberculosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Anti-Tuberculosis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Anti-Tuberculosis Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Anti-Tuberculosis Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Anti-Tuberculosis Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Anti-Tuberculosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Anti-Tuberculosis Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Anti-Tuberculosis Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Anti-Tuberculosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Anti-Tuberculosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Anti-Tuberculosis Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Anti-Tuberculosis Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Anti-Tuberculosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Anti-Tuberculosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Anti-Tuberculosis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Anti-Tuberculosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Anti-Tuberculosis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Anti-Tuberculosis Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Anti-Tuberculosis Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Anti-Tuberculosis Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Anti-Tuberculosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Anti-Tuberculosis Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Anti-Tuberculosis Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Anti-Tuberculosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Anti-Tuberculosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Anti-Tuberculosis Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Anti-Tuberculosis Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Anti-Tuberculosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Anti-Tuberculosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Anti-Tuberculosis Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Anti-Tuberculosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Anti-Tuberculosis Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Anti-Tuberculosis Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Anti-Tuberculosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Anti-Tuberculosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Anti-Tuberculosis Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Anti-Tuberculosis Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Anti-Tuberculosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Anti-Tuberculosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Anti-Tuberculosis Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Anti-Tuberculosis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Anti-Tuberculosis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Anti-Tuberculosis Drug Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Anti-Tuberculosis Drug Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Lupin Company Information
Table 118. Lupin Description and Overview
Table 119. Lupin Anti-Tuberculosis Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 120. Lupin Anti-Tuberculosis Drug Product and Services
Table 121. Lupin Anti-Tuberculosis Drug SWOT Analysis
Table 122. Lupin Recent Developments
Table 123. Otsuka Company Information
Table 124. Otsuka Description and Overview
Table 125. Otsuka Anti-Tuberculosis Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 126. Otsuka Anti-Tuberculosis Drug Product and Services
Table 127. Otsuka Anti-Tuberculosis Drug SWOT Analysis
Table 128. Otsuka Recent Developments
Table 129. Sanofi Company Information
Table 130. Sanofi Description and Overview
Table 131. Sanofi Anti-Tuberculosis Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 132. Sanofi Anti-Tuberculosis Drug Product and Services
Table 133. Sanofi Anti-Tuberculosis Drug SWOT Analysis
Table 134. Sanofi Recent Developments
Table 135. Prizer Company Information
Table 136. Prizer Description and Overview
Table 137. Prizer Anti-Tuberculosis Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 138. Prizer Anti-Tuberculosis Drug Product and Services
Table 139. Prizer Anti-Tuberculosis Drug SWOT Analysis
Table 140. Prizer Recent Developments
Table 141. Abbott Company Information
Table 142. Abbott Description and Overview
Table 143. Abbott Anti-Tuberculosis Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 144. Abbott Anti-Tuberculosis Drug Product and Services
Table 145. Abbott Anti-Tuberculosis Drug SWOT Analysis
Table 146. Abbott Recent Developments
Table 147. NOVARTIS Company Information
Table 148. NOVARTIS Description and Overview
Table 149. NOVARTIS Anti-Tuberculosis Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 150. NOVARTIS Anti-Tuberculosis Drug Product and Services
Table 151. NOVARTIS Anti-Tuberculosis Drug SWOT Analysis
Table 152. NOVARTIS Recent Developments
Table 153. Key Raw Materials Lists
Table 154. Raw Materials Key Suppliers Lists
Table 155. Anti-Tuberculosis Drug Distributors List
Table 156. Anti-Tuberculosis Drug Customers List
Table 157. Anti-Tuberculosis Drug Market Trends
Table 158. Anti-Tuberculosis Drug Market Drivers
Table 159. Anti-Tuberculosis Drug Market Challenges
Table 160. Anti-Tuberculosis Drug Market Restraints
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Tuberculosis Drug Product Picture
Figure 2. Global Anti-Tuberculosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Anti-Tuberculosis Drug Market Share by Type in 2022 & 2034
Figure 4. First-Line Anti-Tuberculosis Drugs Product Picture
Figure 5. Second-Line Anti-Tuberculosis Drugs Product Picture
Figure 6. Global Anti-Tuberculosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Anti-Tuberculosis Drug Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Anti-Tuberculosis Drug Report Years Considered
Figure 12. Global Anti-Tuberculosis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Anti-Tuberculosis Drug Revenue 2018-2034 (US$ Million)
Figure 14. Global Anti-Tuberculosis Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Anti-Tuberculosis Drug Sales Quantity 2018-2034 (K Units)
Figure 16. Global Anti-Tuberculosis Drug Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Anti-Tuberculosis Drug Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Anti-Tuberculosis Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 19. North America Anti-Tuberculosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Anti-Tuberculosis Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. Europe Anti-Tuberculosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Anti-Tuberculosis Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. China Anti-Tuberculosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Anti-Tuberculosis Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. APAC Anti-Tuberculosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Anti-Tuberculosis Drug Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Anti-Tuberculosis Drug Revenue in 2022
Figure 30. Anti-Tuberculosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Anti-Tuberculosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Anti-Tuberculosis Drug Revenue Market Share by Type (2018-2034)
Figure 33. Global Anti-Tuberculosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Anti-Tuberculosis Drug Revenue Market Share by Application (2018-2034)
Figure 35. North America Anti-Tuberculosis Drug Revenue Market Share by Company in 2022
Figure 36. North America Anti-Tuberculosis Drug Sales Quantity Market Share by Company in 2022
Figure 37. North America Anti-Tuberculosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Anti-Tuberculosis Drug Revenue Market Share by Type (2018-2034)
Figure 39. North America Anti-Tuberculosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Anti-Tuberculosis Drug Revenue Market Share by Application (2018-2034)
Figure 41. North America Anti-Tuberculosis Drug Revenue Share by Country (2018-2034)
Figure 42. North America Anti-Tuberculosis Drug Sales Quantity Share by Country (2018-2034)
Figure 43. United States Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Anti-Tuberculosis Drug Sales Quantity Market Share by Company in 2022
Figure 46. Europe Anti-Tuberculosis Drug Revenue Market Share by Company in 2022
Figure 47. Europe Anti-Tuberculosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Anti-Tuberculosis Drug Revenue Market Share by Type (2018-2034)
Figure 49. Europe Anti-Tuberculosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Anti-Tuberculosis Drug Revenue Market Share by Application (2018-2034)
Figure 51. Europe Anti-Tuberculosis Drug Revenue Share by Country (2018-2034)
Figure 52. Europe Anti-Tuberculosis Drug Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 54. France Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 58. China Anti-Tuberculosis Drug Sales Quantity Market Share by Company in 2022
Figure 59. China Anti-Tuberculosis Drug Revenue Market Share by Company in 2022
Figure 60. China Anti-Tuberculosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Anti-Tuberculosis Drug Revenue Market Share by Type (2018-2034)
Figure 62. China Anti-Tuberculosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Anti-Tuberculosis Drug Revenue Market Share by Application (2018-2034)
Figure 64. APAC Anti-Tuberculosis Drug Sales Quantity Market Share by Company in 2022
Figure 65. APAC Anti-Tuberculosis Drug Revenue Market Share by Company in 2022
Figure 66. APAC Anti-Tuberculosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Anti-Tuberculosis Drug Revenue Market Share by Type (2018-2034)
Figure 68. APAC Anti-Tuberculosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Anti-Tuberculosis Drug Revenue Market Share by Application (2018-2034)
Figure 70. APAC Anti-Tuberculosis Drug Revenue Share by Region (2018-2034)
Figure 71. APAC Anti-Tuberculosis Drug Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 76. India Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Anti-Tuberculosis Drug Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Anti-Tuberculosis Drug Revenue Share by Country (2018-2034)
Figure 85. Brazil Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Anti-Tuberculosis Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Anti-Tuberculosis Drug Value Chain
Figure 91. Anti-Tuberculosis Drug Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries